Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$151309.0.

  • Bioadaptives' Cash from Operations fell 16855.45% to -$151309.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$460735.0, marking a year-over-year decrease of 9175.32%. This contributed to the annual value of -$249517.0 for FY2024, which is 1150.45% down from last year.
  • According to the latest figures from Q3 2025, Bioadaptives' Cash from Operations is -$151309.0, which was down 16855.45% from -$110982.0 recorded in Q2 2025.
  • In the past 5 years, Bioadaptives' Cash from Operations ranged from a high of -$19461.0 in Q1 2023 and a low of -$151309.0 during Q3 2025
  • Its 5-year average for Cash from Operations is -$64178.8, with a median of -$56867.0 in 2023.
  • Per our database at Business Quant, Bioadaptives' Cash from Operations tumbled by 25898.4% in 2021 and then skyrocketed by 6817.86% in 2023.
  • Over the past 5 years, Bioadaptives' Cash from Operations (Quarter) stood at -$35403.0 in 2021, then rose by 22.31% to -$27504.0 in 2022, then crashed by 231.94% to -$91296.0 in 2023, then fell by 10.12% to -$100538.0 in 2024, then tumbled by 50.5% to -$151309.0 in 2025.
  • Its Cash from Operations was -$151309.0 in Q3 2025, compared to -$110982.0 in Q2 2025 and -$97906.0 in Q1 2025.